All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 5: Infections
Toggle Parent Pages
Print this page
Principles of antibacterial treatment
Upper respiratory tract infections
Lower respiratory tract infections
Acute exacerbation of bronchiectasis (non-cystic fibrosis)
Urinary tract infections (UTI)
Gastro-intestinal tract infections
Genital tract infections
Skin and soft tissue infections
Eye infections
Oral and dental infections
Lyme disease guidance
Meningitis guidance
Methicillin Resistant Staphylococcus Aureus (MRSA) guidance
COVID-19 treatments for patients who do not require hospitalisation
5.1 Antibacterial drugs
5.2 Antifungal drugs
5.3 Antiviral drugs
5.4 Antiprotozoal drugs
5.5 Anthelmintics
Contact us about this page
5.2.1 Triazole antifungals
First Line
Second Line
Specialist
Hospital Only
Fluconazole
- Capsules 150mg (£0.86 = 1 capsule)
- Capsules 50mg (£0.98 = 7 capsules)
- Intravenous infusion 2mg/ml, 25ml bottle, 100ml bottle
Indications
Itraconazole
- Capsules 100 mg (£4.69 = 15 capsules)
- Oral solution sugar free 50mg/5ml (£53.42 = 150ml)
- Concentrate for intravenous infusion 250mg/25ml
Indications
Isavuconazole
- Capsules 100mg
- Powder for concentrate for solution for infusion 200mg vial
Posaconazole
- Oral suspension 40mg/ml
- Gastro-resistant tablets 100mg
- Intravenous infusion 300mg
Notes
- Tablets not licensed for oropharyngeal candidiasis
- Where possible, tablets should be used in preference to the suspension because the tablets have a higher bioavailability; the suspension is not interchangeable with the tablets on a milligram-for-milligram basis
Voriconazole
- Tablets 50mg, 200mg
- Intravenous infusion 200mg
